Pelthos Therapeutics Inc.
PTHS
$36.31
$1.564.49%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -5.75% | -197.08% | -- | -10.03% | -61.21% |
| Gross Profit | 5.75% | 197.08% | -- | 10.03% | 61.21% |
| SG&A Expenses | 24.53% | 30.72% | 49.24% | 77.89% | 110.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.78% | -5.21% | 10.33% | 129.26% | 158.91% |
| Operating Income | -0.78% | 5.21% | -10.33% | -129.26% | -158.91% |
| Income Before Tax | 7.73% | 18.00% | -7.78% | -118.91% | -162.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.73% | 18.00% | -7.78% | -118.91% | -162.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.73% | 18.00% | -7.78% | -118.91% | -162.31% |
| EBIT | -0.78% | 5.21% | -10.33% | -129.26% | -158.91% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 65.84% | 74.96% | 72.23% | 28.09% | -11.93% |
| Normalized Basic EPS | 64.39% | 73.70% | 71.04% | 26.66% | -11.93% |
| EPS Diluted | 65.84% | 74.96% | 72.23% | 28.09% | -11.93% |
| Normalized Diluted EPS | 64.39% | 73.70% | 71.04% | 26.66% | -11.93% |
| Average Basic Shares Outstanding | 81.01% | 173.15% | 336.45% | 333.05% | 249.68% |
| Average Diluted Shares Outstanding | 81.01% | 173.15% | 336.45% | 333.05% | 249.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |